
Cytomis200 mcg
Incepta Pharmaceuticals Ltd.
Misoprostol is a synthetic prostaglandin E1 analog whose approved and guideline-supported uses differ by clinical setting.
Misoprostol is a synthetic prostaglandin E1 analog whose approved and guideline-supported uses differ by clinical setting. All obstetric use of Misoprostol must occur under direct medical/hospital supervision.
Misoprostol is used together with mifepristone (a combination regimen) for medical termination of early pregnancy, in accordance with local law and clinical guidelines; used alone, Misoprostol is less effective for this purpose than the combination regimen.
Cervical priming/ripening before gynecologic procedures such as hysteroscopy or intrauterine device insertion is a recognized off-label use of Misoprostol in some clinical settings.
Dosing of Misoprostol is specific to the indication and must be directed by a physician; obstetric use requires hospital/clinical monitoring.
| Indication | Typical adult dosing |
|---|---|
| Prevention of NSAID-induced gastric ulcers | 200 mcg orally 4 times daily with food, taken for the duration of NSAID therapy; 100 mcg 4 times daily may be used if 200 mcg is not tolerated. |
| Labor induction / cervical ripening (hospital setting only) | Low-dose regimens such as 25 mcg vaginally every 3–6 hours, per institutional protocol; oral regimens are also used. Continuous fetal and uterine monitoring is required. |
| Prevention of postpartum hemorrhage | Typically 600 mcg administered orally as a single dose immediately after delivery, per WHO guidance, when other uterotonics are unavailable. |
| Treatment of postpartum hemorrhage | Higher single doses (e.g., 600–1000 mcg) by the oral, sublingual, or rectal route, per institutional protocol, as part of comprehensive PPH management. |
| Missed/incomplete miscarriage management; medical termination of pregnancy | Used in specific combination regimens (commonly with mifepristone) and specific doses/routes set by the treating physician in accordance with clinical guidelines and local law. |
Before starting Misoprostol for the NSAID-ulcer-prevention indication, patients of reproductive potential must have a negative pregnancy test and be using effective contraception, because Misoprostol is not to be used in pregnancy for that indication (see Contraindications and Precautions).
The most common side effects of Misoprostol involve the gastrointestinal tract and are generally dose-related:
When Misoprostol is used for obstetric indications, additional effects related to its uterotonic action can occur, including uterine hyperstimulation (excessively frequent or prolonged contractions) and, rarely but seriously, uterine rupture — the risk of which is notably higher in women with a prior cesarean section or other uterine surgery (see Precautions and Warnings).
Misoprostol is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.